ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

The Latest on X

About ASN

ASN / About /

Paul M. Palevsky, MD, FASN

Paul M. Palevsky, MD, FASN, is Professor of Medicine in Clinical and Translational Science in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine, Chief of the Kidney Medicine Section at the VA Pittsburgh Healthcare System and Deputy National Program Director of the VHA Nephrology Program. Dr. Palevsky completed his undergraduate and medical education at Northwestern University in Chicago followed by internship and residency training in internal medicine and fellowship training in nephrology at the Hospitals of the University of Pennsylvania. Following fellowship training, Dr. Palevsky remained at the University of Pennsylvania for one year as a research associate prior to joining the faculty at the University of Pittsburgh in 1989, where he has remained since.

Dr. Palevsky's research has primarily focused on acute kidney injury and critical care nephrology. Among other clinical trials, he was the study chair of the VA/NIH Acute Renal Failure Trial Network (ATN) study, evaluating intensity of renal replacement therapy in critically ill patients with acute kidney injury and as co-chair of the PRESERVE trial, evaluating the comparative effectiveness of saline and bicarbonate and the efficacy of N-acetylcysteine in preventing kidney damage following angiography. He also served as a member of the steering committee for the STOP-GOUT study, comparing the effectiveness of allopurinol and febuxostat. He is currently a principal investigator for the COPE-AKI trial SRTR

Dr. Palevsky is the immediate Past President of the National Kidney Foundation

ASN Highlights - AKI Team

Dr. Palevsky is Professor of Medicine and Clinical and Translational Science in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine and is Chief of the Renal Section at the VA Pittsburgh Healthcare System. Dr. Palevsky completed his undergraduate and medical education at Northwestern University followed by internship and residency training in internal medicine and fellowship training in nephrology at the University of Pennsylvania. Dr. Palevsky joined the faculty at the University of Pittsburgh in 1989, where he has remained since. Dr. Palevsky?s research has primarily focused on AKI and critical care nephrology. He was the study chair of the VA/NIH Acute Renal Failure Trial Network (ATN) study, evaluating intensity of renal replacement therapy in critically ill patients with AKI, and currently serves as co-chair of the PRESERVE trial, evaluating the comparative effectiveness of saline and bicarbonate and the efficacy of N-acetylcysteine in preventing kidney damage following angiography. Among other clinical trials, Dr. Palevsky was a member of the planning and executive committee of the VA NEPHRON-D study, which compared monotherapy with an angiotensin-receptor blocker to combination therapy with both an angiotensin blocker and an angiotensin-converting enzyme inhibitor in slowing progression of diabetic kidney disease; was a member of the steering committees for the EUPHRATES trial, which evaluated extracorporeal endotoxin adsorption in severe sepsis; and is a member of the executive committee of the Stop GOUT trial, comparing the effectiveness of allopurinol to febuxostat in chronic gout. Dr. Palevsky has published more than 200 original articles, reviews, and book chapters, is completing a six-year term as deputy editor of the Clinical Journal of the American Society of Nephrology, and is section editor for Renal Failure for UpToDate. He is a former member of the board of directors and past chair of the Quality, Safety, and Accountability committee of the Renal Physicians Association, is the vice-chair of the board of directors of Quality Insights Renal Network 4 (ESRD Network 4), and is a member of the National Kidney Foundation?s Scientific Advisory Board.